Year None202420232022202120202019 Jan 31, 2024 Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference Jan 29, 2024 Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Jan 22, 2024 ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the Jan 14, 2024 ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Jan 14, 2024 Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% Accord First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Displaying 19 - 23 of 23